Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab.
Adv Skin Wound Care
; 37(2): 1-4, 2024 Feb 01.
Article
em En
| MEDLINE
| ID: mdl-38241457
ABSTRACT
ABSTRACT Dystrophic epidermolysis bullosa pruriginosa (DEB-Pr) is a rare subtype of dystrophic epidermolysis bullosa, and traditional treatments have limited efficacy. Dupilumab has demonstrated remarkable efficacy in relieving pruritus. In this case study, after traditional treatment failed, providers recommended the patient begin dupilumab to treat his pruritus. The patient was administrated a loading dose of 600 mg of dupilumab and a dose of 300 mg every 2 weeks. The Dermatology Life Quality Index and Pruritic Numeric Rating Scale were used to assess the patient's situation. After several months, the patient's DEB-Pr was considered in remission. Dupilumab may be a better choice than immunosuppressants for the treatment of pruritus in patients with DEB-Pr.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Epidermólise Bolhosa Distrófica
/
Epidermólise Bolhosa
Tipo de estudo:
Etiology_studies
Limite:
Humans
Idioma:
En
Revista:
Adv Skin Wound Care
Assunto da revista:
ENFERMAGEM
Ano de publicação:
2024
Tipo de documento:
Article